Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

ICG vs BTBT vs CANF vs IREN vs MARA

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
ICG
Intchains Group Limited

Semiconductors

TechnologyNASDAQ • CN
Market Cap$79M
5Y Perf.-85.3%
BTBT
Bit Digital, Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$580M
5Y Perf.+16.9%
CANF
Can-Fite BioPharma Ltd.

Biotechnology

HealthcareAMEX • IL
Market Cap$25M
5Y Perf.+53.3%
IREN
IREN Limited

Financial - Capital Markets

Financial ServicesNASDAQ • AU
Market Cap$20.30B
5Y Perf.+1900.0%
MARA
Marathon Digital Holdings, Inc.

Financial - Capital Markets

Financial ServicesNASDAQ • US
Market Cap$4.92B
5Y Perf.+48.4%

ICG vs BTBT vs CANF vs IREN vs MARA — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
ICG logoICG
BTBT logoBTBT
CANF logoCANF
IREN logoIREN
MARA logoMARA
IndustrySemiconductorsFinancial - Capital MarketsBiotechnologyFinancial - Capital MarketsFinancial - Capital Markets
Market Cap$79M$580M$25M$20.30B$4.92B
Revenue (TTM)$310M$164M$560K$501M$907M
Net Income (TTM)$20M$137M$-9M$77M$-1.31B
Gross Margin47.0%61.9%100.0%68.3%-47.7%
Operating Margin-1.6%16.8%-16.0%3.5%-90.6%
Forward P/E2.7x9.0x156.9x
Total Debt$272K$14M$104K$964M$3.65B
Cash & Equiv.$322M$95M$5M$565M$547M

ICG vs BTBT vs CANF vs IREN vs MARALong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

ICG
BTBT
CANF
IREN
MARA
StockMar 23May 26Return
Intchains Group Lim… (ICG)10014.7-85.3%
Bit Digital, Inc. (BTBT)100116.9+16.9%
Can-Fite BioPharma … (CANF)100153.3+53.3%
IREN Limited (IREN)1002000.0+1900.0%
Marathon Digital Ho… (MARA)100148.4+48.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: ICG vs BTBT vs CANF vs IREN vs MARA

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: BTBT leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and dividend income and shareholder returns. IREN Limited is the stronger pick specifically for profitability and margin quality and recent price momentum and sentiment. ICG and CANF also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
ICG
Intchains Group Limited
The Income Pick

ICG ranks third and is worth considering specifically for income & stability and growth exposure.

  • Dividend streak 1 yrs, beta 1.81
  • Rev growth 242.7%, EPS growth 490.9%, 3Y rev CAGR -23.6%
  • Lower volatility, beta 1.81, Low D/E 0.0%, current ratio 9.43x
  • Beta 1.81, current ratio 9.43x
Best for: income & stability and growth exposure
BTBT
Bit Digital, Inc.
The Banking Pick

BTBT carries the broadest edge in this set and is the clearest fit for bank quality.

  • NIM 0.1% vs MARA's 0.1%
  • 264.6% NII/revenue growth vs CANF's -9.3%
  • 0.3% yield; the other 4 pay no meaningful dividend
  • 19.0% ROA vs CANF's -114.0%, ROIC 6.5% vs -448.3%
Best for: bank quality
CANF
Can-Fite BioPharma Ltd.
The Defensive Choice

CANF is the clearest fit if your priority is stability.

  • Beta 0.71 vs BTBT's 3.41, lower leverage
Best for: stability
IREN
IREN Limited
The Banking Pick

IREN is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 150.3% 10Y total return vs MARA's -50.7%
  • 17.4% margin vs CANF's -15.7%
  • +7.9% vs ICG's -49.2%
Best for: long-term compounding
MARA
Marathon Digital Holdings, Inc.
The Financial Play

Among these 5 stocks, MARA doesn't own a clear edge in any measured category.

Best for: financial services exposure
See the full category breakdown
CategoryWinnerWhy
GrowthBTBT logoBTBT264.6% NII/revenue growth vs CANF's -9.3%
ValueICG logoICGBetter valuation composite
Quality / MarginsIREN logoIREN17.4% margin vs CANF's -15.7%
Stability / SafetyCANF logoCANFBeta 0.71 vs BTBT's 3.41, lower leverage
DividendsBTBT logoBTBT0.3% yield; the other 4 pay no meaningful dividend
Momentum (1Y)IREN logoIREN+7.9% vs ICG's -49.2%
Efficiency (ROA)BTBT logoBTBT19.0% ROA vs CANF's -114.0%, ROIC 6.5% vs -448.3%

ICG vs BTBT vs CANF vs IREN vs MARA — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

ICGIntchains Group Limited
FY 2024
Product
99.9%$281M
Other Revenue
0.1%$400,000
BTBTBit Digital, Inc.
FY 2024
Other Member
100.0%$550,260
CANFCan-Fite BioPharma Ltd.

Segment breakdown not available.

IRENIREN Limited

Segment breakdown not available.

MARAMarathon Digital Holdings, Inc.
FY 2025
Hosting Services
100.0%$5M

ICG vs BTBT vs CANF vs IREN vs MARA — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLICGLAGGINGMARA

Income & Cash Flow (Last 12 Months)

Evenly matched — BTBT and CANF each lead in 2 of 6 comparable metrics.

MARA is the larger business by revenue, generating $907M annually — 1619.8x CANF's $560,000. IREN is the more profitable business, keeping 17.4% of every revenue dollar as net income compared to CANF's -15.7%. On growth, CANF holds the edge at -36.1% YoY revenue growth, suggesting stronger near-term business momentum.

MetricICG logoICGIntchains Group L…BTBT logoBTBTBit Digital, Inc.CANF logoCANFCan-Fite BioPharm…IREN logoIRENIREN LimitedMARA logoMARAMarathon Digital …
RevenueTrailing 12 months$310M$164M$560,000$501M$907M
EBITDAEarnings before interest/tax-$306,250$166M-$9M-$227M$627M
Net IncomeAfter-tax profit$20M$137M-$9M$77M-$1.3B
Free Cash FlowCash after capex-$28M-$448M-$8M-$690M-$312M
Gross MarginGross profit ÷ Revenue+47.0%+61.9%+100.0%+68.3%-47.7%
Operating MarginEBIT ÷ Revenue-1.6%+16.8%-16.0%+3.5%-90.6%
Net MarginNet income ÷ Revenue+6.5%+17.3%-15.7%+17.4%-144.6%
FCF MarginFCF ÷ Revenue-9.0%-65.3%-14.9%-2.2%-34.4%
Rev. Growth (YoY)Latest quarter vs prior year-64.9%-36.1%
EPS Growth (YoY)Latest quarter vs prior year+50.0%+2.8%+36.4%-6.1%-4.8%
Evenly matched — BTBT and CANF each lead in 2 of 6 comparable metrics.

Valuation Metrics

ICG leads this category, winning 2 of 4 comparable metrics.

At 4.9x trailing earnings, ICG trades at a 97% valuation discount to IREN's 156.9x P/E. On an enterprise value basis, BTBT's 8.3x EV/EBITDA is more attractive than IREN's 104.3x.

MetricICG logoICGIntchains Group L…BTBT logoBTBTBit Digital, Inc.CANF logoCANFCan-Fite BioPharm…IREN logoIRENIREN LimitedMARA logoMARAMarathon Digital …
Market CapShares × price$79M$580M$25M$20.3B$4.9B
Enterprise ValueMkt cap + debt − cash$32M$498M$21M$20.7B$8.0B
Trailing P/EPrice ÷ TTM EPS4.90x9.00x-3.25x156.92x-3.51x
Forward P/EPrice ÷ next-FY EPS est.2.70x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple26.77x8.32x104.33x
Price / SalesMarket cap ÷ Revenue1.92x3.54x37.77x40.52x5.42x
Price / BookPrice ÷ Book value/share0.25x0.55x4.68x7.52x1.32x
Price / FCFMarket cap ÷ FCF
ICG leads this category, winning 2 of 4 comparable metrics.

Profitability & Efficiency

BTBT leads this category, winning 5 of 9 comparable metrics.

BTBT delivers a 21.4% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-2 for CANF. ICG carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MARA's 1.05x. On the Piotroski fundamental quality scale (0–9), ICG scores 6/9 vs CANF's 1/9, reflecting solid financial health.

MetricICG logoICGIntchains Group L…BTBT logoBTBTBit Digital, Inc.CANF logoCANFCan-Fite BioPharm…IREN logoIRENIREN LimitedMARA logoMARAMarathon Digital …
ROE (TTM)Return on equity+2.0%+21.4%-2.1%+3.1%-30.5%
ROA (TTM)Return on assets+1.9%+19.0%-114.0%+1.4%-17.1%
ROICReturn on invested capital+0.4%+6.5%-4.5%+0.7%-9.0%
ROCEReturn on capital employed+0.3%+8.5%-108.1%+0.9%-12.1%
Piotroski ScoreFundamental quality 0–966163
Debt / EquityFinancial leverage0.00x0.03x0.02x0.53x1.05x
Net DebtTotal debt minus cash-$322M-$81M-$5M$400M$3.1B
Cash & Equiv.Liquid assets$322M$95M$5M$565M$547M
Total DebtShort + long-term debt$272,000$14M$104,000$964M$3.6B
Interest CoverageEBIT ÷ Interest expense56.36x-580.71x88.35x4.73x
BTBT leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

IREN leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in IREN five years ago would be worth $25,031 today (with dividends reinvested), compared to $1,550 for ICG. Over the past 12 months, IREN leads with a +788.2% total return vs ICG's -49.2%. The 3-year compound annual growth rate (CAGR) favors IREN at 165.2% vs ICG's -47.4% — a key indicator of consistent wealth creation.

MetricICG logoICGIntchains Group L…BTBT logoBTBTBit Digital, Inc.CANF logoCANFCan-Fite BioPharm…IREN logoIRENIREN LimitedMARA logoMARAMarathon Digital …
YTD ReturnYear-to-date-33.7%-11.8%+1495.5%+43.3%+30.6%
1-Year ReturnPast 12 months-49.2%-13.5%+213.4%+788.2%-9.4%
3-Year ReturnCumulative with dividends-85.5%-21.1%+70.8%+1765.9%+38.7%
5-Year ReturnCumulative with dividends-84.5%-82.8%-82.5%+150.3%-53.5%
10-Year ReturnCumulative with dividends-84.5%-61.0%-99.1%+150.3%-50.7%
CAGR (3Y)Annualised 3-year return-47.4%-7.6%+19.5%+165.2%+11.5%
IREN leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CANF and IREN each lead in 1 of 2 comparable metrics.

CANF is the less volatile stock with a 0.71 beta — it tends to amplify market swings less than BTBT's 3.41 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IREN currently trades 79.6% from its 52-week high vs CANF's 33.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricICG logoICGIntchains Group L…BTBT logoBTBTBit Digital, Inc.CANF logoCANFCan-Fite BioPharm…IREN logoIRENIREN LimitedMARA logoMARAMarathon Digital …
Beta (5Y)Sensitivity to S&P 5001.81x3.41x0.71x3.11x3.10x
52-Week HighHighest price in past year$3.34$4.55$10.40$76.87$23.45
52-Week LowLowest price in past year$0.93$1.25$0.17$6.76$6.66
% of 52W HighCurrent price vs 52-week peak+37.1%+39.6%+33.8%+79.6%+55.2%
RSI (14)Momentum oscillator 0–10050.262.257.663.665.7
Avg Volume (50D)Average daily shares traded432K18.6M1.4M36.1M47.5M
Evenly matched — CANF and IREN each lead in 1 of 2 comparable metrics.

Analyst Outlook

ICG leads this category, winning 1 of 1 comparable metric.

Analyst consensus: ICG as "Buy", BTBT as "Buy", CANF as "Buy", IREN as "Buy", MARA as "Buy". Consensus price targets imply 222.6% upside for ICG (target: $4) vs 9.5% for IREN (target: $67). BTBT is the only dividend payer here at 0.31% yield — a key consideration for income-focused portfolios.

MetricICG logoICGIntchains Group L…BTBT logoBTBTBit Digital, Inc.CANF logoCANFCan-Fite BioPharm…IREN logoIRENIREN LimitedMARA logoMARAMarathon Digital …
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$4.00$5.00$7.25$67.00$16.13
# AnalystsCovering analysts2241319
Dividend YieldAnnual dividend ÷ price+0.3%
Dividend StreakConsecutive years of raises10
Dividend / ShareAnnual DPS$0.01
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%0.0%+1.0%
ICG leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ICG leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). BTBT leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallIntchains Group Limited (ICG)Leads 2 of 6 categories
Loading custom metrics...

ICG vs BTBT vs CANF vs IREN vs MARA: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is ICG or BTBT or CANF or IREN or MARA a better buy right now?

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). Intchains Group Limited (ICG) offers the better valuation at 4. 9x trailing P/E (2. 7x forward), making it the more compelling value choice. Analysts rate Intchains Group Limited (ICG) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — ICG or BTBT or CANF or IREN or MARA?

On trailing P/E, Intchains Group Limited (ICG) is the cheapest at 4.

9x versus IREN Limited at 156. 9x.

03

Which is the better long-term investment — ICG or BTBT or CANF or IREN or MARA?

Over the past 5 years, IREN Limited (IREN) delivered a total return of +150.

3%, compared to -84. 5% for Intchains Group Limited (ICG). Over 10 years, the gap is even starker: IREN returned +150. 3% versus CANF's -99. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — ICG or BTBT or CANF or IREN or MARA?

By beta (market sensitivity over 5 years), Can-Fite BioPharma Ltd.

(CANF) is the lower-risk stock at 0. 71β versus Bit Digital, Inc. 's 3. 41β — meaning BTBT is approximately 381% more volatile than CANF relative to the S&P 500. On balance sheet safety, Intchains Group Limited (ICG) carries a lower debt/equity ratio of 0% versus 105% for Marathon Digital Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — ICG or BTBT or CANF or IREN or MARA?

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -9. 3% for Can-Fite BioPharma Ltd. (CANF). On earnings-per-share growth, the picture is similar: Intchains Group Limited grew EPS 490. 9% year-over-year, compared to -314. 5% for Marathon Digital Holdings, Inc.. Over a 3-year CAGR, CANF leads at -7. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — ICG or BTBT or CANF or IREN or MARA?

Intchains Group Limited (ICG) is the more profitable company, earning 18.

3% net margin versus -1169. 1% for Can-Fite BioPharma Ltd. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BTBT leads at 16. 8% versus -1206. 2% for CANF. At the gross margin level — before operating expenses — CANF leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is ICG or BTBT or CANF or IREN or MARA more undervalued right now?

Analyst consensus price targets imply the most upside for ICG: 222.

6% to $4. 00.

08

Which pays a better dividend — ICG or BTBT or CANF or IREN or MARA?

In this comparison, BTBT (0.

3% yield) pays a dividend. ICG, CANF, IREN, MARA do not pay a meaningful dividend and should not be held primarily for income.

09

Is ICG or BTBT or CANF or IREN or MARA better for a retirement portfolio?

For long-horizon retirement investors, Can-Fite BioPharma Ltd.

(CANF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 71)). Bit Digital, Inc. (BTBT) carries a higher beta of 3. 41 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CANF: -99. 1%, BTBT: -61. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between ICG and BTBT and CANF and IREN and MARA?

These companies operate in different sectors (ICG (Technology) and BTBT (Financial Services) and CANF (Healthcare) and IREN (Financial Services) and MARA (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ICG is a small-cap high-growth stock; BTBT is a small-cap high-growth stock; CANF is a small-cap quality compounder stock; IREN is a mid-cap high-growth stock; MARA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

ICG

Quality Business

  • Sector: Technology
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Stocks Like

BTBT

High-Growth Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 132%
  • Net Margin > 10%
Run This Screen
Stocks Like

CANF

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 60%
Run This Screen
Stocks Like

IREN

High-Growth Compounder

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 83%
  • Net Margin > 10%
Run This Screen
Stocks Like

MARA

High-Growth Disruptor

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 19%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform ICG and BTBT and CANF and IREN and MARA on the metrics below

Revenue Growth>
%
(ICG: -64.9% · BTBT: 264.6%)
Net Margin>
%
(ICG: 6.5% · BTBT: 17.3%)
P/E Ratio<
x
(ICG: 4.9x · BTBT: 9.0x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.